Washington, D.C. Partner David Rosen was quoted in an Inside Health Reform article on July 17, 2013 titled, “FDA Legal Action Holds N.J. Compounder to Manufacturing Standards.” The article discusses a recent consent decree of permanent injunction against a drug compounder that FDA previously flagged mandates the pharmacy follow drug manufacturer standards. Mr. Rosen was quoted saying, “They’re holding them to drug manufacturer-style GMPs.” He also noted that drug companies involved in consent decrees sometimes enter a plan to rehab some of their products, whether it be active pharmaceutical ingredients or ingredients in process, but this must be approved by FDA and there is often a bond to ensure it is carried out.
People
Related News
June 2, 2025
In the News
Judith Waltz on CMS Open Payments Case – 'Plea takes compliance to whole new level'
Foley & Lardner LLP partner Judith Waltz commented in the Report on Medicare Compliance article, "In Guilt Plea Over CMS Open Payments Program, Physician Admits to False Statements."
June 2, 2025
In the News
Foley's Nashville Office Opening, Partner Arrivals Highlighted in Legal Press
May 28, 2025
In the News
Cliff Risman Featured on Hospitality Trends – Transactions at 'almost historic levels'
Foley & Lardner LLP partner Cliff Risman is featured in the Law360 Q&A, "Foley Hospitality Leader Talks Deals In Economic Uncertainty."